Source and purity of dengue-viral preparations impact requirement for enhancing antibody to induce elevated IL-1β secretion: A primary human monocyte model by Callaway, J.B. et al.
Source and Purity of Dengue-Viral
Preparations Impact Requirement for
Enhancing Antibody to Induce Elevated IL-1β
Secretion: A Primary Human Monocyte Model
Justin B. Callaway1,2, Scott A. Smith3,4, Douglas G. Widman1¤, Karen P. McKinnon1,2, 
Frank Scholle5, Gregory D. Sempowski6, Dirk P. Dittmer1,2, James E. Crowe, Jr.3,7,8, 
Aravinda M. de Silva1, Jenny P.-Y. Ting1,2,9*
1 Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, 
NC, United States of America, 2 The Lineberger Comprehensive Cancer Center, The University of North 
Carolina at Chapel Hill, Chapel Hill, NC, United States of America, 3 The Vanderbilt Vaccine Center, 
Vanderbilt Medical Center, Nashville, TN, United States of America, 4 Department of Medicine, Vanderbilt 
Medical Center, Nashville, TN, United States of America, 5 Department of Biological Sciences, North 
Carolina State University, Raleigh, NC, United States of America, 6 Duke Human Vaccine Institute, Durham, 
NC, United States of America, 7 Department of Pathology, Microbiology and Immunology, Vanderbilt 
Medical Center, Nashville, TN, United States of America, 8 Department of Pediatrics, Vanderbilt Medical 
Center, Nashville, TN, United States of America, 9 Department of Genetics, The University of North Carolina 
at Chapel Hill, Chapel Hill, NC, United States of America
¤ Current address: Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, 
NC, United States of America
* jenny_ting@med.unc.edu
Abstract
Dengue virus is a major global health threat and can lead to life-threatening hemorrhagic 
complications due to immune activation and cytokine production. Cross-reactive antibodies 
to an earlier dengue virus infection are a recognized risk factor for severe disease. These 
antibodies bind heterologous dengue serotypes and enhance infection into Fc-receptor-
bearing cells, a process known as antibody-dependent enhancement of infection. One 
crucial cytokine seen elevated in severe dengue patients is IL-1β, a potent inflammatory 
cytokine matured by the inflammasome. We used a highly-physiologic system by studying
antibody-dependent enhancement of IL-1β in primary human monocytes with anti-dengue 
human monoclonal antibodies isolated from patients. Antibody-enhancement increased
viral replication in primary human monocytes inoculated with supernatant harvested from 
Vero cells infected with dengue virus serotype 2 (DENV-2) 16681. Surprisingly, IL-1β secre-
tion induced by infectious supernatant harvested from two independent Vero cell lines was 
not enhanced by antibody. Secretion of multiple other inflammatory cytokines was also
independent of antibody signaling. However, IL-1β secretion did require NLRP3 and cas-
pase-1 activity. Immunodepletion of dengue virions from the infectious supernatant con-
firmed that virus was not the main IL-1β-inducing agent, suggesting that a supernatant
component(s) not associated with the virion induced IL-1β production. We excluded RNA, 
DNA, contaminating LPS, viral NS1 protein, complement, and cytokines. In contrast,
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purified Vero-derived DENV-2 16681 exhibited antibody-enhancement of both infection and
IL-1β induction. Furthermore, C6/36 mosquito cells did not produce such an inflammatory
component, as crude supernatant harvested from insect cells infected with DENV-2 16681
induced antibody-dependent IL-1β secretion. This study indicates that Vero cells infected
with DENV-2 16681may produce inflammatory components during dengue virus propagation
that mask the virus-specific immune response. Thus, the choice of host cell and viral purity
should be carefully considered, while insect-derived virus represents a system that elicits anti-
body-dependent cytokine responses to dengue virus with fewer confounding issues.
Introduction
With an estimated 390 million global infections per year, dengue virus (DENV) is the most
burdensome arbovirus in the world [1]. The four distinct serotypes (DENV-1–DENV-4) are
transmitted by the widespread, tropical Aedes aegypti and Aedes albopictusmosquitoes, and
nearly half of the global population lives in DENV-endemic regions [2]. A first infection with
any serotype may cause an asymptomatic infection or a mild to severe flulike illness referred to
as dengue fever (DF) [3]. Patients typically recover without complication and develop long-
term immunity to the same DENV serotype, but immunity to heterologous serotypes is tran-
sient [4, 5]. Upon later infection with a second serotype of DENV, a small percentage of
patients progress to the life-threatening disease course of severe dengue [2, 4]. During severe
dengue, a reversible permeability develops in the vasculature, causing hemorrhagic manifesta-
tions and potential hypovolemic shock [3, 6]. There is no specific cure or vaccine, but support-
ive therapy until the disease course passes can reduce mortality levels from greater than 20% to
less than 1% [2, 7].
It is now widely accepted that cross-reactive antibodies to a primary infection can increase
disease severity during a heterologous DENV infection [8]. These antibodies may enhance
infection of DENV into Fc-receptor-bearing cells by a mechanism known as antibody-depen-
dent enhancement (ADE) of infection [3, 9]. Circulating CD14+ monocytes, which express
high levels of Fc receptors, have been identified as the primary target of ADE among all periph-
eral blood mononuclear cells (PBMCs), and increased activation of monocytes is associated
with more severe dengue disease [10, 11].
It is believed that a “cytokine storm,” a massive and aberrant upregulation of cytokine produc-
tion, contributes to vascular permeability and hemorrhagic complications [3, 7]. A substantial
number of patient studies have identified the upregulation of a wide array of cytokines during
DENV infection [7, 12–17]. The lack of a consensus on the most damaging cytokines likely
reflects the complicated nature of defining disease severity and achieving consistency between
study parameters. As well, abundant evidence identifies the importance of the specific sequence
of infecting serotypes, with a primary DENV-1 infection followed by a secondary DENV-2 infec-
tion carrying a much higher risk of severe disease development than other combinations [3].
One inflammatory cytokine that is elevated in many cytokine profiles of DENV patients is
IL-1β. Higher levels of circulating IL-1β have been detected in the sera of severe dengue
patients compared to DF patients [12, 18]. Also, 10-fold higher expression of the gene IL1B,
which encodes the pro-IL-1β zymogen, has been measured in PBMCs of severe dengue patients
compared to DF patients [15, 18]. Further, monocytes infected in culture with DENV have
been found to secrete IL-1β [19, 20]. As IL-1β is a potent inflammatory cytokine, its mecha-
nism of production during ADE may provide insight into severe disease pathogenesis.
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The unique regulation of IL-1β production and secretion is generally controlled by a two-
step process. The first step is transcriptional and translational stimulation (such as via NF-κB
activation downstream of TLR signaling) leading to increased expression of IL1B and transla-
tion of the pro-IL-1β zymogen [21]. Alone, pro-IL-1β expression is not sufficient to induce
secretion of active IL-1β. Instead, the second step of the control mechanism is the activation of
the inflammasome [22]. The inflammasome is a large, multi-protein complex typically con-
taining one or more nucleotide-binding domain, leucine-rich repeat containing (NLR) proteins
which, upon assembly, recruit in multiple copies of the pro-caspase-1 zymogen [23–25]. Auto-
catalytic cleavage occurs when pro-caspase-1 proteins come into close association with one
another, forming active caspase-1 [24, 26, 27]. Active caspase-1 subsequently cleaves pro-IL-1β
and pro-IL-18 into mature IL-1β and IL-18 [22, 28]. More recent studies have revealed that
other, non-NLR proteins, such as AIM2 and RIG-I can also form an inflammasome [29, 30].
The stimuli that activate the inflammasome vary by specific NLR component. To date, the
NLRP3 inflammasome is recognized to respond to the widest variety of pathogen- and danger-
associated molecular patterns [23]. Additionally, DENV has been reported to activate the
NLRP3 inflammasome in polarized human macrophages [31].
We have recently shown that ADE of DENV harvested from infected C6/36 mosquito cells
enhances IL-1β secretion by primary human monocytes in a mechanism dependent upon
NLRP3 and caspase-1 [20]. However, DENV is also commonly propagated in Vero cells. Here,
we employed a highly-relevant physiological system utilizing not only primary human mono-
cytes, but also monoclonal antibodies (mAbs) isolated from DENV-immune patients [32, 33],
to study ADE-induced IL-1β using DENV propagated in Vero cells. Interestingly, we found
that inoculation with crude supernatant harvested from Vero cells infected with DENV-2
strain 16681 induced equivalent IL-1β secretion by primary monocytes in the presence or
absence of enhancing antibodies. Further studies indicated that the secretion of IL-1β was
completely independent of antibody signaling and viral replication. Removal of DENV-2
16681 virions from crude supernatant preparations indicated that a soluble component present
in the supernatant was responsible for the induction of IL-1β. In contrast, purified Vero-
derived DENV-2 16681 induced elevated IL-1β secretion only in the presence of ADE. Simi-
larly, crude supernatant harvested from C6/36 mosquito cells infected with DENV-2 16681
induced ADE-dependent IL-1β secretion without the need to purify the viral preparation.
Interestingly, crude supernatant from Vero cells infected with a second DENV strain induced
ADE-dependent IL-1β. Collectively these data indicate that cell-line, strain, and purity selec-
tions during DENV preparation should be carefully considered before undertaking a study
investigating DENV-induced cytokine production.
Results
Primary human monocytes are the main blood cell type infected by
DENV
We first sought to confirm that CD14+ monocytes were the target cell of dengue virus (DENV)
in the current system. Mobilized PBMCs were isolated from leukapheresed blood and inocu-
lated with a multiplicity of infection (MOI) of 50 focus-forming units (ffu) of DENV-2 strain
16681 that had been incubated with 1 μg/ml anti-DENV prM human monoclonal antibody
(mAb) 5G22. Importantly, infectious viral titer was calculated via immunoassay on Vero cells.
Vero cells are highly susceptible to DENV infection, while monocytes are very resistant to the
virus. Thus, an MOI of 50 does not directly translate to 50 times the amount of DENV needed
to infect 1 monocyte. Crude culture supernatant harvested from DENV-infected Vero cells was
cleared of cellular debris and used as the inoculum onto monocytes, hereafter referred to as
DENV-Infectious Vero-cell (DIV) crude supernatant. The human mAb 5G22, isolated from a
DENV-immune patient, is known to potently enhance DENV infection [32].
At 24 hours post-inoculation (hpi), the inoculated PBMCs were analyzed by flow cytometry
for both CD14 and DENV E-protein expression (Fig 1A). Intracellular DENV E protein
detected by flow cytometry is a measure of viral replication [34]. Cells negative for DENV E
Fig 1. DIV crude supernatant induces IL-1β secretion independent of ADE. (A) Flow-cytometric histogram overlay comparing CD14 expression levels in
cells negative or positive for intracellular DENV E protein at 24 hpi. (B) Mobilized monocytes were inoculated with mock medium or DIV crude supernatant
that had been incubated with 1 μg/ml mAb 5G22. At 1 hpi, cells were washed and resuspended in fresh medium. At 24 hpi, cells were washed and stained for
surface expression (left panel) or intracellular expression (right panel) of DENV E protein with mAb 4G2 conjugated to AlexaFluor 647 and analyzed by flow
cytometry. (C) Cumulative percentages of mobilized monocytes positive for intracellular DENV E protein at 24 hpi with DIV crude supernatant in the presence
of increasing concentrations of mAb 5G22. (D) Measurement of secreted IL-1β by ELISA using 24-hpi supernatants from 1C. (E) Repeat of 1C using fresh,
non-mobilized monocytes (one value per point). (F) Measurement of secreted IL-1β using supernatants from 1E (one value per point). (G) Measurement of
DENV E-protein expression in mobilized monocytes at 24 hpi. Cells were inoculated with increasing doses of DIV crude supernatant with or without 1 μg/ml
mAb 5G22. (H) Measurement of secreted IL-1β using 24-hpi supernatants from 1G. (I) Secreted IL-1β by mobilized monocytes at 24 hpi with mock
supernatant or DIV crude supernatant derived from a second line of Vero cells. For all figures: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001,
and “n.s.” = not significant (p > 0.05). Test used: Two-Way ANOVA with Tukey’s post-test (I).
doi:10.1371/journal.pone.0136708.g001
protein expressed varying levels of CD14, while all cells positive for intracellular DENV E pro-
tein also expressed high levels of CD14. These data confirm that CD14+ monocytes are the tar-
get of ADE in a mixed population of PBMCs. Thus, most of the subsequent experiments utilize
cryopreserved CD14+ mobilized monocytes that were purified using negative isolation to
prevent activation through CD14. The advantage of mobilized, leukapheresed blood is that it
provided a large source of cells from a single blood draw (with two separate donors total), elim-
inating much of the variability associated with multiple blood draws from different volunteers
over time. Key phenotypes were verified using CD14+ monocytes purified from fresh draws of
non-mobilized blood.
To verify that this flow-based assay was not detecting DENV adsorbed to the cell surface,
we stained purified mobilized monocytes in the presence or absence of membrane permeabili-
zation (Fig 1B). Inoculation with DIV crude supernatant and mAb 5G22 did not induce ele-
vated DENV E-protein expression in non-permeabilized cells (Fig 1B, left panel). However,
inoculation with DIV crude supernatant and mAb 5G22 induced a shift in DENV E-protein
expression in permeabilized cells (Fig 1B, right panel). These data confirm that this flow-based
assay does not detect surface-adsorbed virus.
DIV crude supernatant induces IL-1β secretion by primary monocytes
independent of enhancement with mAb 5G22
We next examined the induction of IL-1β in primary monocytes by DIV crude supernatant in
the context of ADE. In the absence of mAb 5G22, no intracellular expression of DENV E pro-
tein was detected at 24 hpi in mobilized monocytes (Fig 1C). In contrast, pre-incubation of
DIV crude supernatant with increasing levels of mAb 5G22 caused a dose-dependent increase
in intracellular E-protein expression. Unexpectedly, DIV crude supernatant induced IL-1β
secretion by mobilized monocytes independent of the presence of mAb 5G22, as measured by
ELISA on monocyte supernatants collected at 24 hpi (Fig 1D). An identical pattern was
observed in freshly-isolated monocytes from a non-mobilized donor, with mAb 5G22 required
for intracellular E-protein expression but not for induction of IL-1β secretion (Fig 1E and 1F).
We next inoculated mobilized monocytes with varying doses of DIV crude supernatant in the
presence of a constant antibody dose or control condition. Increasing doses of DIV crude
supernatant increased intracellular E-protein expression in the presence of 1 μg/ml mAb 5G22
(Fig 1G). However, increasing doses of DIV crude supernatant induced elevated secretion of
IL-1β regardless of the presence of mAb 5G22 (Fig 1H). These data indicate a bifurcation in
the dependence on anti-DENV antibody, with mAb 5G22 enhancing DENV replication but
being dispensable for IL-1β secretion in primary monocytes inoculated with DIV crude
supernatant.
To rule out the possibility that these outcomes are unique to the Vero cell line we used,
crude supernatant was harvested from a second, independent line of Vero cells infected with
DENV-2 strain 16681. IL-1β secretion induced by DIV crude supernatant harvested from this
second Vero line also was independent of the presence of mAb 5G22 (Fig 1I). In total, these
results indicate that anti-DENV antibodies significantly impact viral replication in primary
monocytes but are completely dispensable for IL-1β secretion induced by DIV crude
supernatant.
DIV crude supernatant induces broad inflammatory cytokine secretion
independent of ADE
To verify that the lack of ADE-induced IL-1β was not restricted to mAb 5G22, we tested addi-
tional antibody conditions with other human mAbs isolated from DENV-immune patients.
Enhancement of DENV infection with 0.1 μg/ml mAb 2D22 and 2 μg/ml mAb 1C17 (indicated
by peaks with higher DENV E-protein expression in the histograms) both failed to enhance IL-
1β secretion induced by DIV crude supernatant (Fig 2A). In addition to enhancement of infec-
tion, mAb 2D22 also strongly neutralizes DENV-2 infection at higher concentrations, as previ-
ously reported [32]. The use of a neutralizing dose of mAb 2D22 at 2 μg/ml (indicated by the
loss of elevated DENV E-protein expression compared to 0.1 μg/ml 2D22) also did not affect
IL-1β secretion. These data confirm that DIV crude supernatant induces IL-1β secretion inde-
pendent of antibody condition.
To assess if other cytokines are induced in a similar way, we inoculated mobilized mono-
cytes with control medium, DIV crude supernatant alone, or DIV crude supernatant that had
been incubated with 0.1 μg/ml of mAbs 5G22, 1F4, 2D22, or 1C17. Monoclonal antibody 1F4
is specific to DENV-1 and serves as an isotype-matched control antibody [33]. At 24 hpi,
supernatants were collected and assayed for a number of inflammatory cytokines by multiplex
array (Fig 2B–2F). As expected, antibody against DENV did not increase IL-1β secretion
induced by DIV crude supernatant (Fig 2B). DIV crude supernatant also induced elevated
secretion of inflammatory cytokines TNF (Fig 2C), IL-12 (Fig 2D), MIP-1α (Fig 2E), and MIP-
1β (Fig 2F). Various antibodies against DENV did not enhance secretion of these cytokines.
We next antagonized antibody binding by pre-incubating mobilized monocytes with an Fc-
receptor binding inhibitor. Fc-receptor inhibition significantly reduced intracellular, ADE-
induced E-protein expression (Fig 2G) but did not affect the secretion of IL-1β (Fig 2H). In
sum, these data confirm that DIV crude supernatant induces a number of inflammatory cyto-
kines independent of antibody signaling.
IL-1β secretion induced by DIV crude supernatant precedes viral replication
As enhancing viral replication had no effect on IL-1β secretion, we determined if the kinetics of IL-
1β release differ from the kinetics of viral replication. All previous experiments had assessed IL-1β
production at 24 hpi, so we initiated a time course with sample collections at 2, 8, 16, and 24 hpi.
Mobilized monocytes inoculated with DIV crude supernatant, with or without mAb 5G22, secreted
significantly more IL-1β as early as 8 hpi compared to mock conditions (Fig 3A). However, viral
replication only began to elevate significantly at 16 hpi (Fig 3B–3D). Intracellular DENV E-protein
expression could not be detected until 16 hpi with DIV crude supernatant in the presence of mAb
5G22 (Fig 3B). To further assess replication of the virus, the amount of infectious virus present in
the supernatant (Fig 3C) and intracellular presence of DENV genome copies (Fig 3D) were not sig-
nificantly increased until 24 hpi with DIV crude supernatant and mAb 5G22. Importantly, none of
these measures of DENV replication significantly increased when monocytes were inoculated with
DIV crude supernatant in the absence of mAb 5G22. These data confirm that IL-1β secretion
induced by DIV crude supernatant precedes replication and is independent of ADE.
As monocytes are reported to secrete IL-1β within 4 hours of inoculation with DENV [19,
20], we next assessed IL-1β secretion at 4 hpi. DIV crude supernatant induced IL-1β secretion
by 4 hpi in both mobilized monocytes (Fig 3E) and fresh, non-mobilized monocytes (Fig 3F).
These data confirm that IL-1β secretion occurs within 4 hours of inoculation with DIV crude
supernatant. Interestingly, though ADE-enhanced IL-1β secretion has been described at 4 hpi
[19, 20], ADE was dispensable for IL-1β secretion even at 4 hpi in the current system.
IL-1β secretion induced by DIV crude supernatant is independent of viral
replication
Since IL-1β secretion was elevated before replication could be detected, we sought an alternate
way to determine whether infectious DENV was required to induce IL-1β secretion. To do so,

we inactivated DIV crude supernatant by incubation with formalin or exposure to shortwave
UV irradiation prior to inoculation onto mobilized monocytes. Both formalin and UV inacti-
vation ablated intracellular DENV E-protein expression in mobilized monocytes (Fig 3G).
Fig 2. DIV crude supernatant induces inflammatory cytokine secretion independent of antibody
signaling. (A) Left: Flow-cytometric histograms of 24-hpi DENV E-protein expression in mobilized
monocytes after inoculation with mock supernatant, DIV crude supernatant alone, or DIV crude supernatant
that was pre-incubated with 0.1 μg/ml mAb 2D22 (enhancing), 2 μg/ml mAb 2D22 (neutralizing), or 2 μg/ml
mAb 1C17 (enhancing). Right: Measurement of secreted IL-1β at 24 hpi for corresponding samples. (B–F)
Mobilized monocytes were inoculated with mock medium, DIV crude supernatant alone, or DIV crude
supernatant that had been incubated with 0.1 μg/ml of mAbs 5G22, 1F4, 2D22, or 1C17. At 1 hpi, cells were
washed to remove inoculum and resuspended in fresh medium. At 24 hpi, supernatants were collected, and
cytokine secretion was evaluated by multiplex array, including inflammatory cytokines IL-1β (B), TNF (C), IL-
12 (D), MIP-1α (E), and MIP-1β (F). Dashed lines indicate mean concentration induced by mock medium,
except for panel D, in which mock-induced values fell below the lower limit of detection. (G) Measurement of
intracellular DENV E-protein at 24 hpi in mobilized monocytes that were incubated with PBS or Fc-receptor
binding inhibitor prior to inoculation with DIV crude supernatant. (H) Secreted IL-1β at 24 hpi using
supernatants from 2G. Tests used: One-Way ANOVA (within DENV treatment) with Tukey’s post-test (A),
One-Way ANOVA with Dunnett’s post-test (B–F), and Two-Way ANOVA with Bonferroni’s post-test (G and
H).
doi:10.1371/journal.pone.0136708.g002
Fig 3. DIV crude supernatant induces rapid IL-1β secretion independent of viral replication. (A-D) Time course of mobilized monocytes inoculated with
mock supernatant or DIV crude supernatant with or without mAb 5G22. Cells were washed at 1 hpi and resuspended in fresh medium. Samples were
collected at 2, 8, 16, and 24 hpi. (A) Secreted IL-1β. (B) Intracellular DENV E-protein expression. (C) Infectious virus present in the supernatant, as measured
by immunoassay on Vero cells. (D) Relative expression of DENV genome copies in mobilized monocytes, measured by real-time PCR. Values are
normalized to 2 hpi samples in the absence of mAb 5G22. For A-D, data are pooled from two independent experiments. (E) Secreted IL-1β by mobilized
monocytes at 4 hpi. (F) Secreted IL-1β by fresh, non-mobilized monocytes at 4 hpi. (G) Intracellular DENV E-protein expression at 24 hpi with live DIV crude
supernatant or DIV crude supernatant inactivated with formalin or UV exposure, all in the presence of mAb 5G22. (H) Secreted IL-1β at 24 hpi using
supernatants from 3G. Tests used: Two-Way ANOVA with Dunnett’s post-test (A–D), One-Way ANOVA with Dunnett’s post-test (G, H), Two-Way ANOVA
with Tukey’s post-test (E, F). For A and B, gray (A only) and blue asterisks compare DENV and DENV + 5G22, respectively, to mock within each time point.
For C and D, blue asterisks compare DENV + 5G22 to the 2 hpi time point.
doi:10.1371/journal.pone.0136708.g003
However, each inactivated infectious supernatant induced significant elevation of IL-1β secre-
tion compared to mock conditions (Fig 3H). These data indicate that the replication compe-
tency of DENV is dispensable for IL-1β induction by DIV crude supernatant.
DIV crude supernatant induces IL1B and pro-IL-1β expression in primary
monocytes
Elevated secretion of IL-1β can be caused by increased pro-IL-1β expression, increased inflam-
masome activation, or both. To assess the mechanism of IL-1β induction by DIV crude super-
natant, we first considered known cellular expression of key genes by accessing the online
bioinformatics database BioGPS (Fig 4A). CD14+ monocytes express high baseline levels of
CASP1 and NLRP3, which encode the inflammasome components caspase-1 and NLRP3,
respectively. However, basal expression of IL1B is low, indicating it likely needs induction.
Thus, we measured IL1B expression after inoculation of mobilized monocytes with DIV crude
supernatant (Fig 4B). IL1B expression increased rapidly 2 hours after inoculation with DIV
crude supernatant, compared to mock conditions, and gradually reduced over time. Corre-
spondingly, we detected a strong induction of 31-kDa pro-IL-1β expression in the cell lysates
of mobilized monocytes collected 4 hours after inoculation with DIV crude supernatant (Fig
4C). As expected from the ELISA results, mAb 5G22 did not enhance the pro-IL-1β expression
induced by DIV crude supernatant.
Caspase activity and NLRP3 are required for IL-1β secretion induced by
DIV crude supernatant
As mobilized monocytes processed IL-1β after inoculation with DIV crude supernatant, we
next sought to assess inflammasome involvement. We were unable to reproducibly and reliably
detect active caspase-1, a notoriously difficult protein to detect in human cells. However, pre-
treatment of monocytes with the irreversible caspase-1 inhibitor Z-WEHD-FMK at 80 μM sig-
nificantly reduced the IL-1β secretion induced by DIV crude supernatant (Fig 4D). As caspase
inhibitor peptides can be prone to cross-reactivity, we next expanded our caspase studies to uti-
lize low (1 μM) doses of a broad panel of caspase inhibitors (Fig 4E). Inhibitors targeting all
caspases (Z-VAD-FMK), caspases-1, -4, and -5 (Z-WEHD-FMK and Z-YVAD-FMK), cas-
pase-3 (Z-DEVD-FMK), caspase-8 (Z-IETD-FMK), and caspase-9 (Z-LEHD-FMK) all signifi-
cantly reduced IL-1β secretion induced by DIV crude supernatant. This suggests that either cell
death plays an important role in this IL-1β induction or other caspases contribute to inflamma-
some activation. For example, caspase-8 has been found to be important for inflammasome
activation [35, 36].
To test for inflammasome involvement more specifically, we genetically interfered with
NLRP3 expression, as the NLRP3 inflammasome is activated by a wide array of stimuli. We
transfected cells for 24 hours with either a negative control siRNA or one targeting NLRP3
prior to inoculation with DIV crude supernatant (Fig 4F and 4G). At the time of viral inocula-
tion, NLRP3 expression was reduced approximately 63% by the specific siRNA compared to
the negative control (Fig 4F). Expression of NLRC4, an alternate NLR family member, was not
affected. Knockdown of NLRP3 expression significantly reduced the secretion of IL-1β by
mobilized monocytes after inoculation with DIV crude supernatant (Fig 4G). In sum, these
data indicate that caspase activity and NLRP3 activation are required for IL-1β secretion
induced by DIV crude supernatant.
Fig 4. Pro-IL-1β expression induced by DIV crude supernatant requires caspase activity and NLRP3
activation for secretion. (A) Bioinformatic analysis ofCASP1,NLRP3, and IL1B gene expression in various
human immune cells using the publically-available BioGPS datasets. Data is mean + SD (2 values each) of the
measurements for each cell type. Dashed line represents mean of all measured tissues for probe sets listed in
Materials andMethods. (B) Real-time PCRmeasurement of relative IL1B expression bymobilizedmonocytes
that were lysed at indicated time points after inoculation with DIV crude supernatant. Data (mean ± SD of 2
Depletion of antibody-bound virions does not reduce IL-1β secretion
induced by DIV crude supernatant
We next sought to determine the reason that anti-DENV antibodies can enhance DENV repli-
cation without altering the secretion of IL-1β. We considered the possibility that a soluble fac-
tor not associated with the virion could induce signaling in the monocytes. To test this, we
developed a method of depleting antibody-bound virions from DIV crude supernatant (Fig
5A). Antibodies targeting several DENV epitopes were incubated with DIV crude supernatant
individually or in combination. Un-depleted control tubes (fraction C in schematic) received
an equal volume of PBS in lieu of beads. Magnetic protein G beads were incubated in depletion
tubes. Subsequently, depletion tubes were placed on a magnet, sequestering beads, and all
bead-bound components, to the side of the tube. Residual supernatant (fraction R) could then
be collected free of bead-bound components. Finally, the bead-bound fraction (fraction B) was
resuspended to the original volume for analysis. Depleting monoclonal antibodies had specific-
ity for prM, EDI/II, or EDIII, three main antibody targets found on the surface of the DENV
virion, as described previously [37]. Control, residual, and bead-bound fractions were then
assessed by immunoblot for efficiency of DENV depletion (Fig 5B). Under mock conditions
with all three antibodies, DENV E and prM antigens were not detected, as expected. Human
IgG was not detected in the residual fraction depleted of bead-bound components (lane R),
while there was strong detection of human IgG Fc in the bead-bound fraction (lane B). This
indicates that the protein G beads efficiently removed all human IgG. In a second control con-
taining DIV crude supernatant in the absence of antibodies (DENV + PBS), DENV E protein
and prM were only detected in the residual fractions (lane R). This indicates that beads did not
non-specifically bind and deplete DENV virions. Next, each antibody was used individually at
3 μg/ml with DIV crude supernatant. This resulted in varying levels of DENV depletion, as
assessed by the depletion of DENV E or prM proteins from the residual fractions (lane R).
Importantly, the mAb targeting DENV EDI/II removed nearly all detectable virus from the
residual supernatant. Similar results were obtained when all three antibodies were added at
1 μg/ml each with DIV crude supernatant. By contrast, anti-prM and anti-EDIII mAbs only
partially removed DENV virions when compared to their corresponding control supernatants.
Subsequently, both the un-depleted control supernatants (lane C) and antigen-depleted
supernatants (lane R) were inoculated onto mobilized monocytes at an approximate pre-deple-
tion MOI of 50 (Fig 5C). No depletion condition altered IL-1β secretion compared to its
respective un-depleted control supernatant. These data suggest that DENV virions are not
responsible for the IL-1β secretion induced by DIV crude supernatant.
values per condition) are normalized to 2 hpi mock samples. (C) Immunoblot assessing intracellular pro-IL-1β
(31 kDa) in 4 hpi lysates of mobilized monocytes after inoculation with mock supernatant or DIV crude
supernatant in the presence or absence of mAb 5G22. (D) Secreted IL-1β bymobilized monocytes at 5 hpi with
DIV crude supernatant. Cells were pre-treated with DMSO vehicle or 80 μMof Z-WEHD-FMK caspase-1
inhibitor for 30minutes prior to inoculation. (E) Secreted IL-1β bymobilized monocytes at 4 hpi with DIV crude
supernatant. At time of inoculation, monocytes were treated with DMSO vehicle or 1 μM of various caspase
inhibitors: Z-VAD-FMK (pan), Z-WEHD-FMK (1, 4, 5), Z-YVAD-FMK (1, 4, 5), Z-DEVD-FMK (3), Z-IETD-FMK
(8), or Z-LEHD-FMK (9). (F) Assessment ofNLRP3 (target) andNLRC4 (control) expression by real-time PCR,
24 hours after mobilizedmonocytes were transfected with a control siRNA or an siRNA targetingNLRP3. (G)
Secreted IL-1β by knockdown and control cells described in 4F at 6 hpi with mock supernatant or DIV crude
supernatant in the presence of 1 μg/ml 5G22. Monocytes were inoculated 24 hours after siRNA transfection.
Tests used: Two-Way ANOVA with Tukey’s post-test (D), Two-Way ANOVAwith Dunnett’s post-test (E), Two-
Way ANOVAwith Bonferroni’s post-test (G).
doi:10.1371/journal.pone.0136708.g004
Fig 5. Inflammatory component produced by Vero cells during DENV propagation is responsible for IL-1β induction. (A) Schematic depicting the
different depletion and control fractions for depleting antibody-bound virions from DIV crude supernatant by using magnetic protein G beads. (B) Immunoblot
for human IgG Fc, and two DENV structural proteins, E protein and prM, to assess efficiency of antibody-mediated DENV depletion from DIV crude
supernatant. “*” denotes all 3 antibodies were used in combination at 1 μg/ml each. 3 μg/ml of each antibody was used for individual antibody conditions. (C)
Control supernatants (Lane C) and residual supernatants (Lane R) from panel B were inoculated onto mobilized monocytes. Monocyte supernatants were
collected at 24 hpi, and secreted IL-1β was measured by ELISA. (D) Mock and DIV crude supernatants were incubated with PBS or anti-DENV NS1 antibody
prior to addition of protein G beads and subsequent depletion. Top: Residual supernatants (R) and bead-bound fractions (B) were assessed for efficiency of
NS1 depletion by immunoblot. Bottom: Residual supernatants were inoculated onto mobilized monocytes. At 4 hpi, monocyte supernatants were collected
and assessed for secreted IL-1β. (E) Mock and DIV crude supernatants were incubated with PBS, DNase, or Riboshredder prior to inoculation onto mobilized
monocytes. At 4 hpi, monocyte supernatants were collected and assessed for secreted IL-1β. (F) Mobilized monocytes were inoculated with mock
supernatant, live DIV crude supernatant, or DIV crude supernatant that had been incubated for 30 minutes at 56°C to heat inactivate (HI) it. At 24 hpi,
monocyte supernatants were collected and assessed for secreted IL-1β. (G) DIV crude supernatant was centrifuged in an Amicon centrifugal filtration unit
with a 100-kDa molecular-weight cutoff to generate fractions smaller and larger than 100 kDa. Fractions were brought to equal volumes and inoculated onto
mobilized monocytes. At 24 hpi, monocyte supernatants were collected, and IL-1β secretion was measured. Tests used: Two-Way ANOVAwith Bonferroni’s
post-test (D), One-Way ANOVAwith Dunnett’s post-test (F).
doi:10.1371/journal.pone.0136708.g005
Several potential factors eliminated as IL-1β-inducing component of DIV
crude supernatant
To identify the component in DIV crude supernatant that could induce IL-1β secretion, we
investigated several possibilities. First, though most DENV nonstructural proteins are neither
present in an infectious virion nor secreted from infected cells, nonstructural protein 1 (NS1) is
secreted from infected cells as a soluble hexamer [38]. To determine if soluble NS1 present in
DENV supernatant is responsible for the induction of IL-1β secretion, we depleted NS1 from
viral supernatant using antibody-mediated depletion with protein G beads, which resulted in
the near-complete removal of NS1 from DIV crude supernatant (Fig 5D). However, inoculat-
ing mobilized monocytes with NS1-depleted DIV crude supernatant had no impact on the
secretion of IL-1β.
We next verified that DIV crude supernatants were not contaminated with LPS, a potent
IL-1β agonist. Two independent DIV crude supernatant samples were sent to the UNC Tissue
Culture Facility for LPS screening by a limulus amebocyte lysate assay. Both samples were
reported to contain less than or equal to 0.10 Endotoxin Units/ml, thus excluding LPS contam-
ination as a factor.
To investigate the possibility that DENV-infected Vero cells release inflammatory RNA or
DNA, we treated DIV crude supernatant with DNase or RNase prior to inoculation onto mobi-
lized monocytes (Fig 5E). Neither nuclease prevented IL-1β secretion induced by DIV crude
supernatant. Complement has been associated with the response to DENV infection [39]. To
assess if complement or another heat-sensitive component had a role, DIV crude supernatant
was heated for 30 minutes at 56°C prior to inoculation onto mobilized monocytes (Fig 5F).
Heat-inactivated DIV crude supernatant still induced elevated IL-1β secretion over mock
conditions.
To test if cytokines secreted by infected Vero cells, which originated from African green
monkey kidney, could induce IL-1β secretion by primary human monocytes, we filtrated the
DIV crude supernatant. Ultrafiltration of human plasma using a pore with a 60-kDa molecu-
lar-weight cutoff (MWCO) has been shown to effectively remove IL-1β, IL-6, TNFα, IL-10,
and IL-8, as these cytokines are smaller and able to pass through the pore [40]. Thus, we chose
to employ centrifugal filtration with a MWCO of 100 kDa to allow flow-through of cytokines
but not DENV or other larger components. The flow-through fraction, containing everything
less than 100 kDa (approximately), and the concentrated retentate (components above 100
kDa) were collected and brought to equal volumes. Subsequently, equal volumes of both frac-
tions and a mock condition were inoculated onto mobilized monocytes (Fig 5G). Only the frac-
tion containing components larger than 100 kDa induced the secretion of IL-1β by primary
monocytes. This excluded many key cytokines present in Vero-derived supernatant as a con-
tributing factor to IL-1β induction.
Antibody promotes DENV-induced IL-1β secretion by primary
monocytes infected with purified virus
Though the identity of the inflammatory component present in DIV crude supernatant
remained unclear, we wanted to assess if purification of DENV virions away from other super-
natant components would alter the secretion of IL-1β. To purify the virions, DIV crude super-
natant was concentrated and subjected to ultracentrifugation through a 10%–40% continuous
sucrose gradient [41]. Subsequently, mobilized monocytes were inoculated with purified
DENV-2 16681 alone or with mAb 5G22. Similar to the finding with DIV crude supernatant,
intracellular DENV E-protein was only detected in monocytes at 24 hpi in the presence of
mAb 5G22 (Fig 6A). However, unlike that induced by DIV crude supernatant, purified
DENV-2 16681 derived from Vero cells induced significant elevation of IL-1β secretion only in
the presence of mAb 5G22 (Fig 6B). Interestingly, the level of IL-1β induced by purified DENV
is lower than that induced by DIV crude supernatant shown in earlier experiments, consistent
with the presence of an additional inflammatory component in the crude supernatant.
IL-1β induction varies by DENV strain and cell-type used to propagate
virus
We next assessed whether a different DENV strain propagated in Vero cells would similarly
induce ADE-independent IL-1β secretion. In addition to DENV-2 16681, monocytes were
also inoculated with DIV crude supernatant harvested from Vero cells infected with DENV-1
West Pac 74, in the presence or absence mAb 5G22. At 24 hpi, both DENV strains induced
Fig 6. ADE-induced IL-1β secretion varies by DENV purity, strain, and cell-type used for propagation. (A) Mobilized monocytes were inoculated with
mock conditions or purified DENV-2 16681 derived from Vero cells with or without the addition of mAb 5G22. Intracellular DENV E-protein expression was
measured at 24 hpi. (B) Secreted IL-1β detected in 24-hpi monocyte supernatants from 6A. (C) Monocytes were inoculated with DIV crude supernatants
harvested from Vero cells infected with DENV-2 16681 or DENV-1West Pac 74 with or without mAb 5G22. Cells were washed at 1 hpi, and intracellular
DENV E-protein expression was measured at 24 hpi. (D) IL-1β in 24-hpi supernatants from 6C was measured by ELISA. (E) Vero cells were inoculated with
MOI 0.5 of DENV-2 16681 or DENV-1West Pac 74. At 1 hpi, inoculum was aspirated and fresh medium was added. Supernatant samples were collected at
days 1, 3, 5, and 7 post-inoculation and assessed for adenylate kinase release by ToxiLight assay. Values are normalized to the 1 dpi mock condition. (F)
Mobilized monocytes were inoculated with control supernatant from uninfected C6/36 cells or supernatant derived from C6/36 cells infected with DENV-2
16681, with or without 1 μg/ml mAb 5G22. Cells were washed at 1 hpi, and intracellular DENV E-protein expression was analyzed at 24 hpi. (G) Secreted IL-
1β detected in 24-hpi monocyte supernatants from 6E. Tests used: Two-Way ANOVA with Bonferroni’s post-test (B, D, G).
doi:10.1371/journal.pone.0136708.g006
intracellular E-protein expression only when inoculated in the presence of mAb 5G22 (Fig 6C).
Interestingly, the induction of IL-1β varied dramatically by strain (Fig 6D). As before, DENV-2
16681 DIV crude supernatant induced ADE-independent IL-1β secretion. However, DENV-1
West Pac 74 DIV crude supernatant induced IL-1β only under ADE conditions. These data
indicate that IL-1β induced by DIV crude supernatant can vary by DENV strain.
Though grown in Vero cells under the same conditions, we found DENV-1 West Pac 74 to
grow to titers approximately three-fold higher than DENV-2 16681. Thus, inoculating mono-
cytes with equal MOIs of the two strains requires a lower volume of DIV crude supernatant for
DENV-1 West Pac 74. To see if these DENV strains induce cell death in Vero cells, we inocu-
lated Vero cells with equal MOIs of both DENV strains and monitored adenylate kinase (AK)
release over time compared to mock inoculation (Fig 6E). Both DENV strains induced a similar
degree of cell death in Vero cells compared to the mock condition. Thus, increased cell death
alone cannot account for the masking phenotype seen when inoculating monocytes with
DENV-2 16681. However, the lower volume of DIV crude supernatant required to inoculate
monocytes with DENV-1West Pac 74 may reveal ADE-induced IL-1β by exposing monocytes
to a reduced amount of the inflammatory components.
Other studies describing ADE-induced IL-1β secretion in primary monocytes utilized crude
supernatant harvested from DENV-infected C6/36 mosquito cells [19, 20]. We next verified
that crude supernatant harvested from C6/36 cells infected with DENV-2 16681 induced ADE-
dependent IL-1β secretion. Crude supernatant harvested from C6/36 cells infected with
DENV-2 16681 was inoculated onto mobilized monocytes in the presence or absence of mAb
5G22. Similar to Vero-derived DENV-2 16681, mAb 5G22 enhanced the intracellular expres-
sion of DENV E protein in mobilized monocytes 24 hours after inoculation with crude infec-
tious supernatant from C6/36 cells (Fig 6F). As expected based on our previous study [20],
ADE with mAb 5G22 significantly enhanced IL-1β secretion when mobilized monocytes were
inoculated with crude supernatant from C6/36 cells infected with DENV-2 16681 (Fig 6G).
Importantly, the presence of mAb 5G22 did not impact IL-1β secretion induced by crude
supernatant from uninfected C6/36 cells. These data suggest that, unlike Vero cells, C6/36 mos-
quito cells do not produce a potent inflammatory component during the propagation of
DENV-2 16681 in culture. Instead, DENV-2 16681 propagated in mosquito cells displayed
ADE of both infection and IL-1β secretion.
Discussion
This work shows that while all DENV preparations display an identical requirement for ADE
to enhance viral replication, the source and purity of DENV preparations greatly impact the
induction of IL-1β secretion by primary human monocytes. DENV-2 16681 propagation in
Vero cells produced not only high titers of infectious virus, but also inflammatory moieties that
induced IL-1β secretion. Initial experiments utilized debris-cleared supernatant derived from
DENV-infected Vero cells, a common method of viral preparation to analyze the immune
response to DENV [42–46]. This Vero-derived supernatant displayed a strong IL-1β-inducing
activity that was unaltered by ADE, despite concurrent enhancement of infection by antibody.
Crude supernatant harvested from a second, independent line of Vero cells infected with
DENV-2 16681 similarly induced ADE-independent IL-1β secretion. Induction of other
inflammatory cytokines was also independent of ADE. This indicates that an unknown factor
produced by DENV-infected Vero cells may mask the DENV-induced production of numer-
ous cytokines.
Once DENV-2 16681 virions propagated in Vero cells were purified and separated from
other supernatant components, a different phenotype emerged. Purified DENV-2 16681 from
Vero cells induced significantly more IL-1β secretion by monocytes in an ADE-dependent
fashion. ADE similarly enhanced IL-1β secretion when inoculating monocytes with crude
supernatant from C6/36 mosquito cells infected with DENV-2 16681. This indicates that the
inflammatory moiety in Vero-derived supernatant that caused IL-1β secretion is not produced
by mosquito cells. As inoculation with crude supernatant from DENV-infected Vero cells is
commonly used in the field, precaution should be exercised in using such a preparation to
study the DENV-induced inflammatory response in immune cells. However, this phenotype
was not universal amongst DENV strains tested. Crude supernatants harvested from Vero cells
infected with DENV-1West Pac 74 induced ADE-dependent IL-1β. This is possibly because
this virus grows to high titers and thus less virus-containing supernatant was added to cells.
Inoculation of primary mobilized monocytes with crude supernatant from Vero cells
infected with DENV-2 16681 rapidly induced the expression of IL1B and pro-IL-1β. Thus, a
key step leading to elevated IL-1β secretion after inoculation with this supernatant appears to
be the enhancement of pro-IL-1β expression. Although bioinformatic analysis with BioGPS
shows that CASP1 and NLRP3 transcripts are constitutively expressed by human monocytes,
inhibition of caspase-1 with a pharmacologic inhibitor or NLRP3 with RNA interference
reduced the secretion of IL-1β, indicating involvement of the NLRP3 inflammasome.
Although much effort was devoted to identifying the IL-1β-inducing moiety or moieties in
DIV crude supernatant, the nature of the inducer(s) remained elusive. Could it be a cell-culture
artifact that needs to be eliminated from conventional crude viral preparations? Or is this a
physiologically-relevant component (either viral- or host-derived) that merits further study-
ing? Our data suggests that the factor is larger in size than many key cytokines, is heat stable at
56°C, and is not RNA, DNA, or LPS contamination. Further, immunodepletion studies con-
firm that NS1 is not responsible for the IL-1β induction. Of note, one study has shown that
Vero cells infected with DENV undergo more apoptosis than infected C6/36 mosquito cells
[47]. It is possible that by-products of increased cell death may alter the inflammatory pheno-
type of crude supernatant from DENV-infected Vero cells.
The IL-1β-inducing factor present in crude supernatant from Vero cells infected with
DENV-2 16681 likely masked the response induced by DENV and anti-DENV antibody in the
current system. This is an important point to consider, as it can generate misleading results.
Consistent with our results using DENV-1West Pac 74, successful achievement of ADE-
induced cytokines by other groups using crude supernatant derived from DENV-infected Vero
cells indicates that this inflammatory phenotype is not universally produced by all Vero cells or
in all systems [43, 45]. However, a masking component should be considered when disjointed
results between infection and cytokine production are found, particularly under ADE condi-
tions. We have previously shown [20] and confirmed here that crude supernatant from
DENV-infected C6/36 cells does not exhibit these confounding issues and represents a more
straightforward system to study the ADE-induced inflammatory response in human immune
cells. Finally, though the use of purified virus effectively removed the inflammatory moiety




Non-mobilized PBMCs were isolated from fresh blood drawn from a de-identified healthy
donor under Study #13–2115 approved by the University of North Carolina at Chapel Hill
Institutional Review Board and Office of Human Research Ethics, with written informed con-
sent provided. Mobilized peripheral blood mononuclear cells (PBMCs) were isolated from the
blood of leukapheresed patients enrolled in Study #05–2860 approved by University of North
Carolina at Chapel Hill Institutional Review Board and Office of Human Research Ethics after
providing written informed consent. Samples were anonymized and provided as de-identified
samples prior to use in the described studies. The University of North Carolina at Chapel Hill
Office of Human Research Ethics determined that the use of the de-identified samples does not
constitute human subjects research as defined under federal regulations [45 CFR 46.102 (d or
f) and 21 CFR 56.102(c)(e)(l)] and does not require further Institutional Review Board
approval.
PBMC isolation and cell culture
Due to the large number of cells required for this study, we mostly employed cryopreserved,
primary mobilized PBMCs from two separate patients injected with G-CSF, which greatly
increases the number of circulating leukocytes, for further studies [48]. This established a large
stock of monocytes isolated in one day that was capable of supplying months of experiments,
reducing the inherent variability of human studies. We then verified key phenotypes with
PBMCs from freshly-isolated, non-mobilized blood.
PBMCs were isolated from the blood using a 1.073 g/ml Ficoll-Hypaque Premium gradient
(GE Healthcare) to enhance monocyte isolation. The manufacturer’s suggested protocol was
followed for buffy coat isolation. Negative isolation was done using the Dynabeads Untouched
Human Monocytes kit (Invitrogen) by following manufacturer’s protocol. Antibodies against
CD3, CD7, CD16 (specific for CD16a and CD16b), CD19, CD56, CDw123, and CD235a
depleted cells expressing these markers. Mixed PBMCs and purified monocytes were cryopre-
served in 90% heat-inactivated FBS (FBS-HI) with 10% DMSO. On experimental days, cells
were thawed, washed twice, and placed at 37°C for 2 hours in PBMC cell culture media consist-
ing of RPMI with 10% FBS-HI, 1% L-glutamine, 1% NEAA, 1% penicillin/streptomycin, and
30 units/ml DNase to prevent cell clumping from the release of DNA by dying granulocytes.
Cells were counted and resuspended in PBMCmedium without DNase for use in experiments.
The majority of experiments used DENV propagated in the Vero 76 cell line (ATCC CRL-
1587). Confirmation of the inflammatory phenotype with an independent line of Vero cells
was done using DENV propagated in the original Vero cell line, acquired from the UNC Line-
berger Comprehensive Cancer Center Tissue Culture Facility (ATCC CCL-81). The Aedes
albopictus C6/36 cell line was acquired from ATCC (CRL-1660).
DENV-specific antibodies
Crude supernatant of mAb D14G2 (4G2), a pan-flavivirus E-protein specific mouse IgG2a
mAb, for use in IHC viral titrations was kindly provided by Dr. Mariano Garcia-Blanco of
Duke University. Purified mAb 4G2 was generated by the UNC Antibody Core Facility. The
isolation and purification of human mAbs 5G22 (α-prM used for enhancement and depletion),
2D22 (α-DENV-2 used for enhancement and neutralization), 6B22 (α-EDI/II used for deple-
tion), 1C17 (α-EDIII used for enhancement and depletion), 1F4 (α-DENV-1 used for isotype-
matched control) and 2H21 (α-prM used for immunoblots) were described in detail previously
[32, 33].
Virus stock growth
All experiments used DENV-2 strain 16681, kindly provided by Dr. Robert Tesh of UTMB-
Galveston, unless otherwise noted. Vero cells were cultured at 37°C with 5% CO2 in MEM
+ 6% FBS-HI, 1% penicillin/streptomycin, and 20 mMHEPES buffer. To generate large stocks
for experiments, near-confluent Vero cell culture monolayers were inoculated with DENV-2
16681 or DENV-1 West Pac 74 at an MOI of 0.5 in low-volume, low-serum conditions, placed
in the incubator, and rocked every 15 minutes. At 2 hpi, culture medium was added. For viral
stocks grown for purification, 1% FBS-HI was used so as not to clog the centrifugal filters dur-
ing the concentration step. At days 3, 7, and 10, medium was collected from the flasks and cen-
trifuged at 4,000 RPM for 10 minutes to clarify the supernatants. Infectious crude supernatants
were then aliquoted into tubes for freezing at -70°C. Fresh medium replaced the collected
supernatants. C6/36 cells were cultured at 29.5°C with 5% CO2 in MEM + 10% FBS-HI, 1%
NEAA, 1% penicillin/streptomycin, and 20 mMHEPES. Propagation of DENV in C6/36 cells
was done as with Vero cells except for listed differences in medium composition.
We modified a previously described protocol to quantitate the infectious titer of viral stocks
[49]. Briefly, near-confluent Vero cell monolayers in flat-bottom, 96-well plates were inocu-
lated with 50 μl of sequential 10-fold dilutions of DENV stocks. At 2 hpi, an overlay of 150 μl
of 1.6% carboxymethylcellulose (diluted 1:1 in 2X MEM and supplemented with 1% FBS-HI,
10 mMHEPES and 1X antibiotics) was added to limit spread of virus. At 72 hpi, cells were
fixed using a 1:1 mixture of acetone and methanol. Fixed cells were blocked with 2% normal
horse serum in PBS and subsequently stained for 1 hour using mAb 4G2 as the primary anti-
body (1:500 dilution of crude supernatant into blocking solution) and 1:1000 goat anti-mouse
IgG-HRP (KPL) as the secondary antibody. Viral foci were visualized using Vector VIP Peroxi-
dase Substrate kit (Vector Laboratories, Inc.) and counted under a dissecting microscope, with
titers calculated as Vero focus forming units per ml (ffu/ml).
Inoculation of PBMCs or monocytes
One hour pre-inoculation, dilutions of enhancing antibodies or control medium were plated
into 96-well, round-bottom, non-tissue-culture treated plates. Crude infectious supernatants or
purified DENV preparations were diluted to the appropriate multiplicity of infection (MOI)
and mixed with antibodies or control medium. DENV and antibody mixtures were incubated
for 1 hour at 37°C with 5% CO2 to allow immune complex formation. For mock infection
wells, spent culture medium from uninfected Vero cell or C6/36 cultures was used instead of
infectious supernatant. MEM with 1% FBS-HI, 1% penicillin/streptomycin, and 20 mM
HEPES was used as the mock condition for purified virus. After the 1 hour incubation for com-
plex formation, mixed PBMCs or purified primary monocytes were added. At 1–2 hours post-
inoculation (hpi), cells were washed at least 2 times with PBS and resuspended in fresh culture
medium. At collection, cells were resuspended and pelleted by centrifugation. After two washes
with 1X PBS (four for genome copy studies), cells were fixed with Cytofix/Cytoperm (BD Bio-
sciences) for 20 minutes at 4°C for flow cytometry, lysed with RLT Lysis Buffer (Qiagen) for
RNA analysis, or lysed with 1X RIPA buffer (Boston BioProducts) with protease inhibitors
(Roche) for western blot analysis. Monocyte supernatants were centrifuged to clear cells and
debris, recollected, and stored at 4°C until analysis by ELISA. Unless otherwise noted, all
monocyte inoculations were done with an MOI of 50.
Flow cytometry
Purified mAb 4G2 was conjugated to Alexa Fluor 647 using the Alexa 647 Protein Labeling Kit
(Life Technologies) according to manufacturer’s instructions. After labeling, the labeled anti-
body was titrated by staining known DENV-positive monocytes to identify the best dilution
for detection of DENV E protein without high levels of non-specific background in mock-inoc-
ulated cells.
For detection of DENV E protein, cells were washed twice with Perm/Wash buffer (BD Bio-
sciences) after fixation and re-suspended in 25 μl of Human Fc Receptor Binding Inhibitor
(eBiosciences) diluted 1:5 in Perm/Wash Buffer for 15 minutes at 4°C. Cells were then incu-
bated with 25 μl of mAb 4G2 conjugated to Alexa Fluor 647 diluted 1:250 in Perm/Wash buffer
for 30 minutes at 4°C. Cells were then washed twice with Perm/Wash buffer and finally re-sus-
pended in 200 μl of Perm/Wash buffer for analysis on a Cyan ADP flow cytometer (Dako).
Cells were initially gated on FSC-area vs. SSC-area, with single cells positively selected for by
gating cells on the diagonal of FSC-height vs. FSC-area. Cells positive for DENV E-protein
were detected on the APC channel, with positive gates set based on the mock-inoculated
controls.
For surface detection of DENV E protein, cells at 24 hpi were washed with PBS and then
resuspended in 25 μl of Human Fc Receptor Binding Inhibitor diluted 1:5 in FACS buffer (2%
FBS in PBS) and incubated for 15 minutes at 4°C. Cells were then incubated with 25 μl of mAb
4G2 conjugated to Alexa Fluor 647 diluted 1:250 in FACS buffer for 30 minutes at 4°C. Cells
were then washed twice with FACS buffer and resuspended in 50 μl of fresh PBS. Cells were
then resuspended with 50 μl of 2% formalin diluted into PBS and allowed to incubate at room
temperature for 20 minutes protected from light. Cells were then washed twice with FACS
buffer and resuspended with 200 μl fresh FACS buffer. Stained cells were stored at 4°C pro-
tected from light until analysis by flow cytometry.
For staining of surface CD14 expression in conjunction with intracellular DENV E-protein
expression, cells were washed twice with PBS and incubated at 4°C with Human Fc Receptor
Binding Inhibitor in eFluor NC Flow Cytometry Staining Buffer (eBiosciences) supplemented
with 2% FBS-HI for 15 minutes at 1 test per well. Cells were then stained with anti-human
CD14 eFluor 605NC mouse mAb (eBiosciences) at 1 test size per well in 25 μl 1X staining
buffer and incubated for 30 minutes in the dark at 4°C. Cells were washed twice with staining
buffer, fixed, permeabilized, and stained with mAb 4G2 conjugated to Alexa Fluor 647, as
described above. An unstained control and single-stained controls were set up for gating analy-
sis. For compensation, antibodies were added to anti-mouse BD CompBeads at same dilution
as sample staining. Cells and beads were run on a LSRII flow cytometer (Becton Dickinson),
using the APC channel for the anti-DENV antibody and QDot605 for the anti-CD14 antibody.
Compensation calculations and analysis were done using FlowJo.
Real-time PCR
After lysis with RLT buffer, cell lysates were passed through QIAshredder columns (QIAGEN)
to homogenize lysates. Homogenized lysates were then added to RNA isolation columns from
RNeasy Mini kits (QIAGEN), and all steps were followed as detailed in the manufacturer’s pro-
tocol. RNA was eluted in a volume of 30 μl RNase/DNase free water. To generate cDNA, 1 μl
Random Primers (3 μg/μl; Invitrogen) and 1 μl dNTP Mix (10 mM; Invitrogen) was added to
10 μl of eluted RNA and heated at 65°C for 5 minutes in a PTC-225 Peltier Thermal Cycler
(MJ Research). Tubes were chilled on ice and 4 μl Invitrogen 5X First Strand Buffer, 2 μl Invi-
trogen 0.1M DTT, and 1 μl Promega RNasin RNase Inhibitor (40 units/μl) were added to each
tube and incubated at 37°C for 2 minutes. Then 1 μl Invitrogen M-MLV Reverse Transcriptase
(200 units/μl) was added per tube, and tubes were incubated at 25°C for 10 minutes and 37°C
for 50 minutes, with an inactivation step of 70°C for 15 minutes.
For real-time PCR analysis, 9 μl cDNA was added to 1 μl 20X TaqMan Gene Expression
Assay mix (Applied Biosystems [ABI]) and 10 μl of ABI 2X TaqMan Universal PCR Master
Mix in a 384-well plate. Samples were pipetted in triplicate. Plates were run on an ABI 7900
HT Fast Real-Time PCR machine using the following parameters: 50°C for 2 minutes, 95°C for
10 minutes, and 40 repeats of 95°C for 15 seconds followed by 60°C for 1 minute. Fold change
values were calculated using the ΔΔCt method, normalized to a control value set at 1. Where
applicable, all biological replicates (including their corresponding pipetting triplicates) were
combined and outliers greater than 2 standard deviations away from the mean were excluded.
For all samples, 18s rRNA was used as the housekeeping-gene control.
The following ABI TaqMan Gene Expression Assays were used for real-time PCR analysis
of gene expression: assay Hs01555410_m1 was used for IL1B, Hs00918082_m1 was used for
NLRP3, Hs00368367_m1 was used for NLRC4, and Hs03928985_g1 was used for RN18S1. For
DENV genome copies, a custom TaqMan Gene Expression Assay was designed using nucleo-
tides 10635–10708, a portion of the 30 UTR of DENV conserved between all 4 serotypes, identi-
fied and described by Gurukumar, et al. [50].
Caspase inhibition
For inhibition of caspase-1 only, Z-WEHD-FMK Caspase-1 Inhibitor (R&D Systems) was
diluted in sterile DMSO and cells were pre-treated with 80 μMZ-WEHD-FMK or DMSO vehi-
cle 30 minutes prior to inoculation with DENV. Dilutions were made into cell culture medium.
For the caspase inhibition panel, Z-VAD-FMK (pan caspase inhibitor), Z-WEHD-FMK
and Z-YVAD-FMK (caspases-1, -4, and -5 inhibitors), Z-DEVD-FMK (caspase-3 inhibitor),
Z-IETD-FMK (caspase-8 inhibitor), and Z-LEHD-FMK (caspase-9 inhibitor) (all from R&D
Systems) were diluted in sterile DMSO and given to the cells at a final concentration of 1 μM
each at the time of inoculation with DIV crude supernatant.
Bioinformatic analysis
The publicly available BioGPS expression database was used for all bioinformatic analysis [51].
The U133A, gcrma dataset was used for analysis of the following genes: CASP1 (probeset
206011_at), NLRP3 (probeset 207075_at), and IL1B (probeset 205067_at) [52].
Gene knockdown
Knockdown of NLRP3 was achieved using QIAGEN’s HiPerFect Transfection Reagent and
FlexiTube GeneSolution GS114548 for NLRP3. QIAGEN’s AllStars Negative Control siRNA
served as a negative control for NLRP3 knockdown. Briefly, based upon manufacturer’s
instructions, concentrations of both transfection reagent and siRNAs were optimized in a pilot
experiment. Knockdown was analyzed by decrease of NLRP3 expression as analyzed by real-
time PCR compared to control. For the experimental knockdown, 4 x 106 cells per condition
were plated in 7 ml of growth medium in a 150 mm dish. 8 μl of each 10 mM stock of NLRP3
siRNAs was added to 1 total ml of serum-free RPMI (16 μl of 20 mM negative control siRNA).
Then, 20 μl of HiPerFect transfection reagent was added to each tube, vortexed, and allowed to
incubate at room temperature. After 10 minutes, complexes were dripped onto the cells, plates
were swirled, and allowed to incubate for 24 hours. At 24 hours post-transfection, cells were
collected, counted, and immediately used for infection assays.
SDS-PAGE and immunoblots
For protein studies to be analyzed by immunoblot, primary monocytes were lysed in the
96-well plates using RIPA Buffer (Boston BioProducts) containing 1X Complete Protease
Inhibitor (Roche). Plates were rocked at 4°C for 20 minutes. Lysates were collected and centri-
fuged at 13,000 RPM for 10 minutes to clear debris. Lysates were recollected into fresh tubes.
4X NuPAGE LDS Sample Buffer (Life Technologies), containing 20 mg/ml DTT reducing
reagent (Roche), was added to a final concentration of 1X. Samples were mixed and heated at
97°C for 5 minutes.
For viral protein analysis by immunoblot, NuPAGE LDS Sample Buffer without DTT was
added directly to DENV-containing supernatant to a final concentration of 1X. Samples were
vortexed and heated at 97°C for 10 minutes. DTT was added to samples at above concentra-
tions for detection of DENV NS1 by immunoblot.
Samples were loaded in NuPAGE 4–12% Bis-Tris pre-cast gels (Life Technologies) and sep-
arated by SDS-PAGE using 1X NuPAGEMES SDS running buffer (Life Technologies). Gels
were transferred onto 0.2 μm nitrocellulose membranes (Bio-Rad) under wet transfer condi-
tions using 1X Transfer Blotting Buffer (Boston BioProducts) with 30% methanol for 45 min-
utes at a constant 100V. Membranes were blocked in a 10% milk solution in TBS-T for 1 hour
at room temperature. Primary antibodies were incubated overnight at 4°C with rotation at the
following dilutions in blocking buffer: 1:1,000 rabbit polyclonal antibody anti-IL-1β (Santa
Cruz sc-7884), 1 μg/ml purified mouse mAb 4G2 to detect DENV E protein, 1 μg/ml human
mAb 2H21 to detect DENV prM, 1:1000 goat anti-human Fc conjugated to HRP (Bethyl
Laboratories) to detect human IgG Fc, or 1:1000 rabbit anti-DENV NS1 polyclonal antibody
(Genetex GTX103346). After 4 washes with TBS-T, the membranes were incubated with the
following secondary antibodies diluted into blocking buffer for 2 hours at room temperature:
1:5000 goat anti-rabbit HRP-conjugate (Santa Cruz) for IL-1β and NS1, 1:5000 goat anti-
mouse HRP-conjugate (Santa Cruz) for DENV E protein, or 1:5000 goat anti-human HRP con-
jugate (Bethyl) for DENV prM. Human IgG in depletion studies was detected directly after pri-
mary antibody incubation because of HRP conjugate. Membranes were then washed 4–5 times
with TBS-T and subsequently developed after 5 minute incubations with Thermo Scientific
SuperSignal West Pico Chemiluminescent Substrate.
Depletion of antibody-bound virions and NS1
Mock and DIV crude supernatants were incubated with indicated concentrations of antibodies
(or equal volume of PBS control) for 1 hour on ice. Subsequently, either 50 μl of pre-washed
Dynabeads Protein G beads (Life Technologies) or equal volume of PBS were added to samples,
and placed on a rotator at 4°C for 1 hour. Tubes were then placed onto a DynaMag-2 magnet
for 1 minute, and bead-free supernatants were collected and transferred to a new tube. Place-
ment on the magnet with collection of the supernatant was repeated two more times to ensure
complete removal of beads. The bead-free supernatants beads were considered the residual
fractions, while the resuspended beads (for protein analysis only) were considered the bead-
bound fractions. Tubes that had PBS added in lieu of beads were considered the control frac-
tions, as equal volumes were maintained but no antigens were depleted. Depletion of NS1 was
done identically by using mouse anti-NS1 monoclonal antibody clone DN1 (Abcam #ab41490)
to immunoprecipitate NS1 with protein G beads. Monoclonal antibody DN1 was washed
through an Amicon filter to remove preservatives, resuspended in PBS at a 6-fold increase in
concentration, and then syringe filtered to purify. This was then used at a final dilution of 1:2
for successful depletion of NS1.
DNase and RNase treatment of viral supernatant
Mock and DIV crude supernatants were incubated with 30 units/ml of amplification grade
DNase I (Life Technologies), 6 units/ml RiboShredder RNase Blend (Epicentre), or an equal
volume of PBS. Samples were incubated for 20 minutes at room temperature for DNase activ-
ity, 20 minutes at 37°C for RNase activity, and finally 12 minutes at 65°C followed by 2 minutes
at 97°C to ensure inactivation of the enzymes prior to inoculation onto cells.
Virus purification
To purify virus, a previously described protocol was used [41]. Briefly, crude supernatants
from DENV-infected Vero cells were concentrated by centrifugation at 1500 x g for 20–25
minutes in 15 ml Millipore Amicon Centrifugal Filter Units with a 100-kDa cutoff, allowing
components< 100 kDa to pass through but not virus. The final concentrated volume was
approximately 2 ml, which was gently layered on top of an 8-ml 10% -40% continuous sucrose
gradient in an ultracentrifuge tube. The gradient was centrifuged in a Beckman Coulter Optima
L-90K Ultracentrifuge using rotor SW40TI for 2.5 hours at 35,000 RPM and 4°C with no
brake. Sequential 0.5 ml fractions were collected from the bottom of the ultracentrifuge tube
into microfuge tubes. Fractions 4–8 were pooled and washed to remove sucrose using another
15 ml Amicon tube. After 2 washes, the virus was resuspended in MEM with 1% FBS-HI, 20
mMHEPES, and 1% penicillin/streptomycin. The pooled fractions were then titered as
described earlier.
Virus inactivation
DIV crude supernatant was inactivated using formalin or shortwave UV exposure. For forma-
lin inactivation, 0.25% formalin (final concentration) was added to an aliquot of virus stock
and allowed to incubate at room temperature for 2.5 hours. For shortwave UV inactivation,
100 μl/well of virus stock was added to each well of a 24-well plate, placed on ice, and exposed
to shortwave UVB (254 nm) irradiation for 2 min at a distance of approximately 5 cm. After
inactivation, the inactivated supernatants, and an equal volume of live virus, were added into
separate 15 ml Amicon tubes and washed twice using fresh medium to remove formalin (or as
control for sample loss for supernatants not treated with formalin). After washing, the superna-
tants were resuspended in fresh culture medium to equal volumes and inoculated onto
monocytes.
Cytokine detection
Detection of human IL-1β in the supernatant was done using BD Biosciences’ BD OptEIA
Human IL-1beta ELISA Set II. The kit was followed as per manufacturer’s instructions, and the
absorbance at 450 nm was read on a PerkinElmer EnSpire Multimode Reader 2300. Wave-
length correction at 570 nm was used.
Detection of human IL-1β, IL-12, TNF, MIP-1α, and MIP-1β for Fig 2B–2F was done by
assaying 50 μl of 24 hpi supernatants in the Invitrogen Human Cytokine 25-Plex Luminex
Bead Panel according to manufacturer’s instructions in the Regional Biocontainment Labora-
tory at Duke Immunology Unit (Duke University, Durham, NC).
Adenylate kinase release
Adenylate kinase release into culture supernatants was assessed by ToxiLight (Lonza). Super-
natants were stored at -70°C until the assay was run. Then, 20 μl of culture supernatant was
mixed with 100 μl of adenylate kinase detection reagent. After 5 minutes, luminescence was
measured by plate reader. Cell-free media controls collected at each time point were subtracted
from each sample, and values were normalized to the mock condition at day 1.
Illustration
Schematic illustration of immunodepletion strategy was generated by modifying images pur-
chased in the PPT Drawing Toolkits—BIOLOGY Bundle fromMotifolio, Inc.
Data presentation and statistical analysis
Graphs are presented as mean ± SEM of 3 or more biological replicates, unless otherwise
noted. All statistical analyses were done with 3 or more replicate values per group. Student’s
unpaired, two-tailed t tests were used when making comparison between only 2 means. One-
way ANOVAs were employed to compare the means of 3 or more groups within one indepen-
dent variable. Two-way ANOVAs were used for comparisons between two independent vari-
ables (e.g. viral treatment vs. antibody treatment). Asterisks for comparisons done by One-
Way or Two-Way ANOVA represent the multiplicity-adjusted p values from multiple compar-
isons tests. Multiple comparisons tests were selected as follows: Dunnett’s post-test for compar-
ing all means to a single control value, Bonferroni’s post-test for comparing only means within
one independent variable, and Tukey’s post-test for comparing all means for all independent
variables. Choice of post-test was dependent on desired comparisons and is indicated in figure
legends. Analyses were done using GraphPad Prism 6.0. Statistical outliers (p< 0.05) were
excluded from graphs and analysis using Grubbs’ test on the GraphPad website. For all figures,
statistical significance was defined as p< 0.05 (), but all comparisons were also tested for
p< 0.01 (), p< 0.001 (), and p< 0.0001 (). “n.s.” = not significant.
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